Copyright
©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1047-1063
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1047
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1047
Table 2 Chemotherapy regimens, n (%)
| RTCh | Ch | |
| (n = 40) | (n = 27) | |
| Cisplatin-Etoposide | 19 (47.5) | 0 |
| Cisplatin-Vinorelbine | 14 (35) | 6 (22.2) |
| Cisplatin-Pemetrexed | 4 (10) | 3 (11.1) |
| Cisplatin-Docetaxel | 0 | 6 (22.2) |
| Cisplatin-Gemcitabine | 0 | 2 (7.4) |
| Carboplatin-Vinorelbine | 3 (7.5) | 1 (3.7) |
| Carboplatin-Paclitaxel | 0 | 6 (22.2) |
| Carboplatin-Pemetrexed | 0 | 1 (3.7) |
| Carboplatin-Gemcitabine | 0 | 2 (7.4) |
- Citation: Muñoz-Guglielmetti D, Sanchez-Lorente D, Reyes R, Martinez D, Lucena C, Boada M, Paredes P, Parera-Roig M, Vollmer I, Mases J, Martin-Deleon R, Castillo S, Benegas M, Muñoz S, Mayoral M, Cases C, Mollà M, Casas F. Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations. World J Clin Oncol 2021; 12(11): 1047-1063
- URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1047.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1047